BioNexus Gene Lab holder reports 392,329 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
FIDELION DIAGNOSTICS PTE. LTD. is identified as a greater than 5% holder of BioNexus Gene Lab Corp and reports direct ownership of 392,329 shares of common stock. This Form 3 serves as an initial statement of holdings and does not report any specific purchase or sale transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Common Stock | -- | -- | -- |
Key Figures
Key Terms
Greater than 5% holder regulatory
Common Stock financial
Unknown transaction code regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the BioNexus Gene Lab Corp (BGLC) Form 3 report about Fidelion Diagnostics' holdings?
Is Fidelion Diagnostics a director or officer of BioNexus Gene Lab Corp (BGLC)?
Does the BGLC Form 3 show any buy or sell transactions by Fidelion Diagnostics?
What type of ownership does Fidelion Diagnostics have in BioNexus Gene Lab Corp (BGLC)?
AI-generated analysis. How Rhea-AI works. Not financial advice.